• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

The Top 5 Biosimilars Articles for the Week of July 22


The Center for Biosimilars® recaps the top stories for the week of July 22, 2019.


Hi, I’m Jaime Rosenberg for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of July 22, 2019.

Number 5: Sandoz announced that it has enrolled its first patient in a study of a proposed biosimilar, GP2411.

Number 4: The European Medicines Agency will review Samsung Bioepis’ proposed biosimilar, SB8.

Number 3: A new paper argues that regulators should affirm the interchangeability of approved biosimilars.

Number 2: The FDA approved its fourth adalimumab biosimilar on Tuesday.

Number 1: Also on Tuesday, the FDA approved its second rituximab biosimilar.

Finally, last week, our e-newsletter asked whether you think that advocacy groups will play a role in US biosimilar uptake.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.

Related Videos
Prerakkumar Parikh, PharmD
Cencora's Corey Ford
Brian Biehn
GBW 2023 webinar
Fran Gregory, PharmD, MBA
Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health
Here are the top 5 biosimilar articles for the week of May 1, 2023.
Christine Baeder
Here are the top 5 biosimilar articles for the week of February 13th, 2023.
Michael Kleinrock
Related Content
© 2024 MJH Life Sciences

All rights reserved.